Received Jul 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
suspected vaccination failure; shingles and it was in his ear; post herpetic neuralgia; significant pain; This serious case was reported by a physician via sales rep and described the occurrence of vaccination failure in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: suspected vaccination failure) (serious criteria GSK medically significant), herpes zoster oticus (Verbatim: shingles and it was in his ear) (serious criteria GSK medically significant), post herpetic neuralgia (Verbatim: post herpetic neuralgia) and pain (Verbatim: significant pain). The outcome of the vaccination failure, herpes zoster oticus, post herpetic neuralgia and pain were not reported. It was unknown if the reporter considered the vaccination failure, herpes zoster oticus, post herpetic neuralgia and pain to be related to Shingrix. The company considered the vaccination failure and herpes zoster oticus to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 23-JUL-2026 The batch number was not provided and unable to contact the reporter. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure and Herpes zoster oticus, unknown time after vaccination with 1st dose and 2nd dose of Shingrix, in a adult male patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.